RLMD — RELMADA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1553643 ·
Last close
$3.83
Market Cap
$408.55M
52W High
$8.00
52W Low
$1.62
ADV30
1,133,173
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -15,011,027 | -12,914,185 | 219,059,177 | 11,334,370 | 12,500,854 |
| Mar 2026 | 0 | — | -19,461,754 | -19,051,956 | 235,362,794 | 9,776,400 | 16,630,217 |
| Dec 2025 | 0 | — | -20,333,112 | -19,867,760 | 94,003,471 | 3,496,540 | 7,491,458 |
| Sep 2025 | 0 | — | -10,327,346 | -10,091,496 | 14,876,244 | 1,384,484 | 5,410,705 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-42,787,443
Investing CF
$-198,725,016
Financing CF
$250,139,153
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.40
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-717,319,154
Inventory
—
Receivables
—
ST Investments
$224,186,743
EBIT TTM
$-60,343,518
Pretax Income TTM
$-58,877,654
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -59,100,200 | -57,385,163 | 94,003,471 | 7,491,458 | 86,512,013 | -45,786,988 |
| Dec 2024 | 0 | -83,891,036 | -79,979,354 | 45,817,818 | 10,295,857 | 35,521,961 | -51,755,798 |
| Dec 2023 | 0 | -103,702,293 | -98,791,746 | 97,552,042 | 12,194,800 | 85,357,242 | -51,659,206 |
| Dec 2022 | 0 | -161,249,076 | -157,043,823 | 152,905,179 | 12,468,877 | 140,436,302 | -103,801,617 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.56
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $3.83 · call volume: 505 · put volume: 51
Expected Move to 2026-11-20:
±$1.13
(29.50%) —
implied range
$2.70 –
$4.96
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPRY | ARS Pharmaceuticals, Inc. | $405.75M | $4.08 | — |
| CTNM | Contineum Therapeutics, Inc. | $413.96M | $12.56 | — |
| AVIR | Atea Pharmaceuticals, Inc. | $414.66M | $5.17 | — |
| IRD | Opus Genetics, Inc. | $396.01M | $4.76 | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $393.66M | $13.85 | — |
News headlines (Yahoo Finance, 1h cache)
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
2026-08-31 13:35 · Yahoo
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
2026-08-25 13:55 · Yahoo
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
2026-08-11 13:35 · Yahoo
Relmada Therapeutics Q2 Earnings Call Highlights
2026-08-07 11:03 · Yahoo
Relmada Therapeutics Inc (RLMD) (Q2 2026) Earnings Call Highlights: Strong Phase 2 Data and FDA ...
2026-08-07 05:09 · Yahoo
Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 20:05 · Yahoo
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
2026-07-28 12:30 · Yahoo
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
2026-07-16 11:05 · Yahoo
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
2026-06-29 11:00 · Yahoo
Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now
2026-06-19 07:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.